News & Press Releases
News & Press Releases
News & Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Psyence BioMed’s Texas subsidiary, TIRC, has partnered with Benuvia to establish a pathway for US ibogaine manufacturing. The agreement aims to support pharmaceutical-grade production in Texas for future regulated research and clinical development, subject to applicable DEA quotas and regulatory authorisations.
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
syence BioMed’s Texas subsidiary has signed a binding term sheet with PsyLabs covering exclusive U.S. ibogaine development, supply and distribution rights. The parties aim to conclude a definitive agreement by November 30, 2026.
Psyence BioMed Announces Strategic Ibogaine Investment
Psyence BioMed has agreed to invest up to US$5 million in PsyLabs and pursue a share exchange to support manufacturing and development for its planned US ibogaine program. A potential Texas clinical trial remains under evaluation.
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed welcomes renewed federal support for ibogaine development and outlines how its pharmaceutical manufacturing platform can contribute to responsible clinical research in the United States.
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
News and Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
